News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Athera Biotechnologies and Boehringer Ingelheim Corporation Enter Into an Option Agreement on a Novel Therapy for Atherosclerosis


6/19/2013 9:38:50 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STOCKHOLM, SWEDEN – June 19, 2013. Athera Biotechnologies AB today announced that it has entered into an option agreement with Boehringer Ingelheim International GmbH on a novel preclinical antibody program, whereby Athera grants to Boehringer Ingelheim an exclusive option to acquire the entire program. Karolinska Development AB owns 65% of Athera Biotechnologies AB. Athera’s fully-human monoclonal antibody is intended for the treatment of patients with cardiovascular disease, who are at an increased risk of secondary events and death.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES